LUXA / Lux Health Tech Acquisition Corp - Class A - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

LUXA / Lux Health Tech Acquisition Corp / Lux Encore Sponsor, LP - SC 13G/A Passive Investment

SC 13G/A 1 d224554dsc13ga.htm SC 13G/A United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Lux Health Tech Acquisition Corp. (Name of Issuer) Class A c

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39657 LUX HEALTH TECH ACQUISITION CORP. (Exact name of registrant as spe

Lux Health Tech Acquisition Corp. Announces Cancellation of Special Meeting of Stockholders and Liquidation

Exhibit 99.1 Lux Health Tech Acquisition Corp. Announces Cancellation of Special Meeting of Stockholders and Liquidation New York, NY ? October 7, 2022 ? Lux Health Tech Acquisition Corp. (the ?Company?) today announced that it has cancelled its special meeting of stockholders that was previously scheduled for 9:00 AM Pacific time on October 13, 2022, and that, because the Company will not consumm

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 7, 2022 Date of Report (Date of earliest event reported) Lux Health Tech Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39657 85-2825321 (State or other jurisdiction of incorporation) (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ?Preliminary Proxy Statement ?Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ?Definitive Proxy Statemen

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ?Preliminary Proxy Statement ?Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ?Definit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ?Preliminary Proxy Statement ?Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ?Definitive Proxy Statemen

Lux Health Tech Acquisition Corp. Signs Letter of Intent for a Business Combination

Exhibit 99.1 Lux Health Tech Acquisition Corp. Signs Letter of Intent for a Business Combination New York, NY ? September 6, 2022 ? Lux Health Tech Acquisition Corp. (the ?Company?) today announced that it has entered into a non-binding letter of intent (?LOI?) for a business combination with a leading life sciences company addressing significant unmet needs in some of the most costly and debilita

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 6, 2022 Date of Report (Date of earliest event reported) Lux Health Tech Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39657 85-2825321 (State or other jurisdiction of incorporation)

Lux Health Tech Acquisition Corp. 920 Broadway, 11th Floor New York, NY 10010

Lux Health Tech Acquisition Corp. 920 Broadway, 11th Floor New York, NY 10010 August 31, 2022 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn:Babette Cooper Wilson Lee Office of Real Estate & Construction Re: Lux Health Tech Acquisition Corp. Form 10-K for the Fiscal Year Ending December 31, 2021 Filed March 30, 2022 File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to LUX HEALTH TECH ACQUISITION CORP. (Exact name of regist

PROMISSORY NOTE

Exhibit 10.1 THIS PROMISSORY NOTE (THIS ?NOTE?) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COM

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 25, 2022 Date of Report (Date of earliest event reported) Lux Health Tech Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39657 85-2825321 (State or other jurisdiction of incorporation) (Com

LUXA / Lux Health Tech Acquisition Corp / Sculptor Capital LP - SC 13G Passive Investment

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* LUX HEALTH TECH ACQUISITION CORP. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 55068A100 (CUSIP Number) May 17, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to LUX HEALTH TECH ACQUISITION CORP. (Exact name of regis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39657 Lux Health Tech A

LUXA / Lux Health Tech Acquisition Corp / D1 Capital Partners L.P. - LUX HEALTH TECH ACQUISITION CORP. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Lux Health Tech Acquisition Corp. (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of Securities) 55068A100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r

LUXA / Lux Health Tech Acquisition Corp / Weiss Asset Management LP Passive Investment

=============================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

LUXA / Lux Health Tech Acquisition Corp / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 2) LUX HEALTH TECH ACQUISITION CORP. (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 55068A100 (CUSIP Number) DECEMBER 31, 2021 (Date of event which requires filing of this statement) Check the appropriate bo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-396

Promissory Note, dated December 3, 2021, issued by Lux Health Tech Acquisition Corp. to Lux Encore Sponsor, LP

Exhibit 10.1 THIS PROMISSORY NOTE (THIS ?NOTE?) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COM

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

a United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 3, 2021 Date of Report (Date of earliest event reported) Lux Health Tech Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39657 85-2825321 (State or other jurisdiction of incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-CEN ? Form N-CSR For Period Ended: September 30, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q For the Transition Period Ended: Read Instruction (on back page) Before Preparing Form.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to LUX HEALTH TECH ACQUISITION CORP. (Exact name of r

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 12 2021 Date of Report (Date of earliest event reported) Lux Health Tech Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39657 85-2825321 (State or other jurisdiction of incorporation) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to LUX HEALTH TECH ACQUISITION CORP. (Exact name of regist

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to LUX HEALTH TECH ACQUISITION CORP. (Exact name of regis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39657 Lux Health Tech

Exhibit A

Exhibit A Pursuant to the instructions in Item 6 of Schedule 13G, the following lists the identity of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment No. 2 Under the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment No. 2 Under the Securities Exchange Act of 1934 Lux Health Tech Acquisition Corp. (Name of Issuer) Class A common stock, $0.0001 par value per share (Title of Class of Securities) 55068A100 (CUSIP Number) 12/31/20 (Date of Event which Requires Filing of this Statement) Check the appropriate box to design

Lux Health Tech Acquisition Corp. Receives Expected Notice From Nasdaq Regarding Delayed Quarterly Report

Exhibit 99.1 Lux Health Tech Acquisition Corp. Receives Expected Notice From Nasdaq Regarding Delayed Quarterly Report May 28, 2021 New York, NY - (BUSINESS WIRE) - Lux Health Tech Acquisition Corp. (the ?Company?) announced today that, on May 28, 2021, it received a notice (?Notice?) from the Listing Qualifications Department of The Nasdaq Stock Market (?Nasdaq?) stating that the Company is not i

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Other Events

United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 28, 2021 Date of Report (Date of earliest event reported) Lux Health Tech Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39657 85-2825321 (State or other jurisdiction of incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-CEN ? Form N-CSR For Period Ended: March 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q For the Transition Period Ended: Read Instruction (on back page) Before Preparing Form.

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 18, 2021 Date of Report (Date of earliest event reported) Lux Health Tech Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39657 85-2825321 (State or other jurisdiction of incorporation) (Comm

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39657 Lux Health Tech A

Description of registered securities.*

Exhibit 4.5 Description of the Company?s Securities Registered Under Section 12 of the Exchange Act of 1934 The following description of our units, common stock and warrants is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our amended and restated certificate of incorporation, bylaws and warrant agreement, each of which are incorporat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Lux Health Tech Acquisition Corp. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 55068A100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Lux Health Tech Acquisition Corp. (Name of Issuer) Units (Title of Class of Securities) 55068A209 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: X Rule 13d

Joint Filing Agreement.

EX-99 CUSIP No. 55068A100 Schedule 13G Page 9 of 9 Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness a

United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE

SC 13G United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Lux Health Tech Acquisition Corp. (Name of Issuer) Class A common stock, par value $0.0001 pe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) LUX HEALTH TECH ACQUISITION CORP. (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Tit

SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) LUX HEALTH TECH ACQUISITION CORP. (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 55068A100 (CUSIP Number) DECEMBER 31, 2020 (Date of event which requires filing of this statement) Check the a

Lux Health Tech Acquisition Corp.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Lux Health Tech Acquisition Corp. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 55068A100 (CUSIP Number) January 14, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Lux Health Tech Acquisition Corp.lux (Name of Issuer) Class A common stock, $0.0001 par value per share (Title of Class of Securities) 55068A100 (CUSIP Number) 12/31/20 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 11, 2020 Lux Health Tech Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware 001-39657 85-2825321 (State or other jurisdiction of incorporation)

Lux Health Tech Acquisition Corp. Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing December 14, 2020

Exhibit 99.1 Lux Health Tech Acquisition Corp. Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing December 14, 2020 December 11, 2020 New York, NY - (BUSINESS WIRE) - Lux Health Tech Acquisition Corp. (the “Company”) announced that, commencing December 14, 2020, holders of the units sold in the Company’s initial public offering (the “Units”) may elect to separately

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Lux Health Tech Acquisition Corp. (Exact name of r

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 29, 2020 Lux Health Tech Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware 001-39657 85-2825321 (State or other jurisdiction of incorporation)

LUX HEALTH TECH ACQUISITION CORP.

Exhibit 99.1 LUX HEALTH TECH ACQUISITION CORP. Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of October 29, 2020 F-3 Notes to Financial Statement F-4 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Stockholders and Board of Directors of Lux Health Tech Acquisition Corp. Opinion on the Financial Statement We have audited the accompanying balance sheet o

Passive Investment -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 LUX HEALTH TECH ACQUISITION CORP. (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 55068A209** (CUSIP Number) OCTOBER 27, 2020 (Date of event which requires filing of this statement) Check the appropriate box to designate th

Registration Rights Agreement, dated October 26, 2020, among the Company and certain security holders named therein. (1)

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of October 26, 2020, is made and entered into by and among Lux Health Tech Acquisition Company, a Delaware corporation (the “Company”), Lux Encore Sponsor, LP, a Delaware limited partnership (the “Sponsor”), and the undersigned parties listed under Holder on the signature pages hereto (each s

Indemnity Agreement, dated October 26, 2020, between the Company and Dr. Fred Moll. (1)

Exhibit 10.12 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of October 26, 2020, by and between Lux Health Tech Acquisition Corp., a Delaware corporation (the “Company”), and Dr. Fred Moll (the “Indemnitee”). RECITALS WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers or in other capacities unless the

Indemnity Agreement, dated October 26, 2020, between the Company and Senator Joseph Robert “Bob” Kerrey. (1)

Exhibit 10.11 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of October 26, 2020, by and between Lux Health Tech Acquisition Corp., a Delaware corporation (the “Company”), and Sen. Bob Kerrey (the “Indemnitee”). RECITALS WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers or in other capacities unless t

Indemnity Agreement, dated October 26, 2020, between the Company and Josh DeFonzo. (1)

Exhibit 10.8 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of October 26, 2020, by and between Lux Health Tech Acquisition Corp., a Delaware corporation (the “Company”), and Josh DeFonzo (the “Indemnitee”). RECITALS WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers or in other capacities unless they

Underwriting Agreement, dated October 26, 2020, between the Company and Credit Suisse Securities (USA) LLC, as representative of the several underwriters.

EXHIBIT 1.1 30,000,000 Units Lux Health Tech Acquisition Corp. UNDERWRITING AGREEMENT October 26, 2020 Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, NY 10010-3629 As Representative of the several Underwriters listed in Schedule I hereto Dear Ladies and Gentlemen: 1.Introductory. Lux Health Tech Acquisition Corp., a Delaware corporation (the “Company”), agrees with the several

Indemnity Agreement, dated October 26, 2020, between the Company and Segolene Scarborough. (1)

Exhibit 10.9 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of October 26, 2020, by and between Lux Health Tech Acquisition Corp., a Delaware corporation (the “Company”), and Segolene Scarborough (the “Indemnitee”). RECITALS WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers or in other capacities unle

Second Amended and Restated Certificate of Incorporation, dated October 26, 2020. (1)

Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LUX HEALTH TECH ACQUISITION CORP. October 26, 2020 Lux Health Tech Acquisition Corp., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY AS FOLLOWS: 1.The name of the Corporation is “Lux Health Tech Acquisition Corp.” The original certificate of incorporation o

Sponsor Warrants Purchase Agreement, dated October 23, 2020, between the Company and the Sponsor. (1)

Exhibit 10.3 PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT THIS PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT, dated as of October 23, 2020 (as it may from time to time be amended and including all exhibits referenced herein, this “Agreement”), is entered into by and between Lux Health Tech Acquisition Corp., a Delaware corporation (the “Company”), Lux Encore Sponsor, LP, a Delaware limited partne

Letter Agreement, dated October 26, 2020, between the Company and the Sponsor. (1)

Exhibit 10.5 October 26, 2020 Lux Health Tech Acquisition Corp. 920 Broadway, 11th Floor New York, NY 10010 Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, NY 10010 Re: Initial Public Offering Ladies and Gentlemen: This letter (the “Letter Agreement”) is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) entered into by and betwee

Lux Health Tech Acquisition Corp. Announces Pricing of $300 Million Initial Public Offering

Exhibit 99.1 Lux Health Tech Acquisition Corp. Announces Pricing of $300 Million Initial Public Offering October 26, 2020 NEW YORK - (BUSINESS WIRE) - Lux Health Tech Acquisition Corp. (the “Company”) announced today the pricing of its initial public offering of 30,000,000 units at a price of $10.00 per unit. The units will be listed on the Nasdaq Stock Market, LLC (“Nasdaq”) and will trade under

Warrant Agreement, dated October 26, 2020, between the Company and Continental Stock Transfer & Trust Company, as warrant agent. (1)

Exhibit 4.1 Execution Version WARRANT AGREEMENT between LUX HEALTH TECH ACQUISITION CORP. and CONTINENTAL STOCK TRANSFER & TRUST COMPANY Dated as of October 26, 2020 THIS WARRANT AGREEMENT (this “Agreement”), dated as of October 26, 2020, is entered into by and between Lux Health Tech Acquisition Corp., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New Y

Indemnity Agreement, dated October 26, 2020, between the Company and Peter Hébert. (1)

Exhibit 10.7 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of October 26, 2020, by and between Lux Health Tech Acquisition Corp., a Delaware corporation (the “Company”), and Peter Hebert (the “Indemnitee”). RECITALS WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers or in other capacities unless they

Forward Purchase Agreement, dated October 22, 2020, among the Company, Lux Ventures VI, L.P. and Lux Ventures VI Sidecar, L.P. (1)

Exhibit 10.4 FORWARD PURCHASE AGREEMENT This Forward Purchase Agreement (this “Agreement”) is entered into as of October 22, 2020, between Lux Health Tech Acquisition Corp., a Delaware corporation (the “Company”), Lux Ventures VI, L.P., a Delaware limited partnership, and Lux Ventures VI Sidecar, L.P., a Delaware limited partnership (together, the “Purchasers”). RECITALS WHEREAS, the Company was f

Investment Management Trust Agreement, dated October 26, 2020, between the Company and Continental Stock Transfer & Trust Company, as trustee. (1)

Exhibit 10.1 INVESTMENT MANAGEMENT TRUST AGREEMENT This Investment Management Trust Agreement (this “Agreement”) is made effective as of October 26, 2020 by and between Lux Health Tech Acquisition Corp., a Delaware corporation (the “Company”) and Continental Stock Transfer & Trust Company, a New York limited purpose trust company (the “Trustee”). WHEREAS, the Company’s registration statement on Fo

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

ne UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 26, 2020 Lux Health Tech Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware 001-39657 85-2825321 (State or other jurisdiction of incorporatio

Indemnity Agreement, dated October 26, 2020, between the Company and Dr. Bijan Salehizadeh. (1)

Exhibit 10.10 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of October 26, 2020, by and between Lux Health Tech Acquisition Corp., a Delaware corporation (the “Company”), and Dr. Bijan Salehizadeh (the “Indemnitee”). RECITALS WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers or in other capacities un

Lux Health Tech Acquisition Corp. Announces Closing of $345 Million Initial Public Offering

Exhibit 99.2 Lux Health Tech Acquisition Corp. Announces Closing of $345 Million Initial Public Offering October 29, 2020 New York - (BUSINESS WIRE) - Lux Health Tech Acquisition Corp. (the “Company”) announced today the closing of its initial public offering of 34,500,000 units, which included the full exercise of the underwriters’ over-allotment option, at a price of $10.00 per unit, resulting i

Letter Agreement, dated October 26, 2020, between the Company and each of its officers and directors. (1)

Exhibit 10.6 October 26, 2020 Lux Health Tech Acquisition Corp. 920 Broadway, 11th Floor New York, NY 10010 Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, NY 10010 Re: Initial Public Offering Ladies and Gentlemen: This letter (the “Letter Agreement”) is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) entered into by and betwee

Lux Health Tech Acquisition Corp. 30,000,000 Units

Filed Pursuant to Rule 424(b)(4) Registration No. 333-249427 PROSPECTUS Lux Health Tech Acquisition Corp. $300,000,000 30,000,000 Units Lux Health Tech Acquisition Corp. is a newly incorporated blank check company whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or ent

-

October 23, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.

-

LUX TECH HEALTH Acquisition CoRP. 920 Broadway, 11th Floor New York, New York 10010 (646) 475-4385 October 23, 2020 Via Edgar Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-4628 Attn: Liz Packebusch, Staff Attorney Laura Nicholson, Special Counsel Office of Energy & Transportation Re: Lux Health Tech Acquisition Corp. Registration State

- 8-A12B

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Lux Health Tech Acquisition Corp. (Exact Name of Registrant as Specified in Its Charter) Delaware 85-2825321 (State of Incorporation or Organization) (I.R.S. Employer Identification No.) 920 Broadway, 11t

- S-1/A

As filed with the U.S. Securities and Exchange Commission on October 22, 2020. Registration No. 333-249427 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Lux Health Tech Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware 6770 85-2825321 (State or other jurisdi

Form of Second Amended and Restated Certificate of Incorporation.**

Exhibit 3.3 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LUX HEALTH TECH ACQUISITION CORP. [ ● ], 2020 Lux Health Tech Acquisition Corp., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY AS FOLLOWS: 1.The name of the Corporation is “Lux Health Tech Acquisition Corp.” The original certificate of incorporation of the

Form of Underwriting Agreement.**

Exhibit 1.1 30,000,000 Units Lux Health Tech Acquisition Corp. UNDERWRITING AGREEMENT [●], 2020 Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, NY 10010-3629 As Representative of the several Underwriters listed in Schedule I hereto Dear Ladies and Gentlemen: 1.Introductory. Lux Health Tech Acquisition Corp., a Delaware corporation (the “Company”), agrees with the several Underwr

Form of Warrant Agreement between Continental Stock Transfer & Trust Company and Lux Health Tech Acquisition Corp.**

Exhibit 4.4 FORM OF WARRANT AGREEMENT between LUX HEALTH TECH ACQUISITION CORP. and CONTINENTAL STOCK TRANSFER & TRUST COMPANY Dated as of [ ● ], 2020 THIS WARRANT AGREEMENT (this “Agreement”), dated as of , 2020, is entered into by and between Lux Health Tech Acquisition Corp., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York limited purpose trust

Specimen Class A Common Stock Certificate. (2)

Exhibit 4.2 SPECIMEN CLASS A COMMON STOCK CERTIFICATE NUMBER NUMBER C- SHARES SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP LUX HEALTH TECH ACQUISITION CORP. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE CLASS A COMMON STOCK This Certifies that is the owner of FULLY PAID AND NON-ASSESSABLE SHARES OF THE PAR VALUE OF $0.0001 EACH OF THE CLASS A COMMON STOCK OF LUX HEALTH TECH ACQUISITION CORP. (

Specimen Warrant Certificate. (2)

Exhibit 4.3 SPECIMEN WARRANT CERTIFICATE [FACE] Number Warrants THIS WARRANT SHALL BE VOID IF NOT EXERCISED PRIOR TO THE EXPIRATION OF THE EXERCISE PERIOD PROVIDED FOR IN THE WARRANT AGREEMENT DESCRIBED BELOW LUX HEALTH TECH ACQUISITION CORP. Incorporated Under the Laws of the State of Delaware CUSIP Warrant Certificate This Warrant Certificate certifies that , or registered assigns, is the regist

Form of Investment Management Trust Agreement between Continental Stock Transfer & Trust Company and Lux Health Tech Acquisition Corp.**

Exhibit 10.3 FORM OF INVESTMENT MANAGEMENT TRUST AGREEMENT This Investment Management Trust Agreement (this “Agreement”) is made effective as of [ ● ], 2020 by and between Lux Health Tech Acquisition Corp., a Delaware corporation (the “Company”) and Continental Stock Transfer & Trust Company, a New York limited purpose trust company (the “Trustee”). WHEREAS, the Company’s registration statement on

-

Lux Health Tech Acquisition Corp. 920 Broadway, 11th Floor New York, NY 10010 October 22, 2020 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn:Liz Packebusch, Staff Attorney Laura Nicholson, Special Counsel Office of Energy & Transportation Re: Lux Health Tech Acquisition Corp. Registration Statement on Form S-1 Filed Oct

Form of Letter Agreement among the Registrant and each director and executive officer of the Registrant.**

Exhibit 10.2 [ ● ], 2020 Lux Health Tech Acquisition Corp. 920 Broadway, 11th Floor New York, NY 10010 Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, NY 10010 Re: Initial Public Offering Ladies and Gentlemen: This letter (the “Letter Agreement”) is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) entered into by and between Lux

Specimen Unit Certificate. (2)

Exhibit 4.1 SPECIMEN UNIT CERTIFICATE NUMBER UNITS U- SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP LUX HEALTH TECH ACQUISITION CORP. UNITS CONSISTING OF ONE SHARE OF CLASS A COMMON STOCK AND ONE-THIRD OF ONE WARRANT TO PURCHASE ONE SHARE OF CLASS A COMMON STOCK THIS CERTIFIES THAT is the owner of Units. Each Unit (“Unit”) consists of one (1) share of Class A common stock, par value $0.0001 per share

Form of Forward Purchase Agreement among Lux Health Tech Acquisition Corp., Lux Ventures VI, L.P. and Lux Ventures VI Sidecar, L.P.**

Exhibit 10.9 FORWARD PURCHASE AGREEMENT This Forward Purchase Agreement (this “Agreement”) is entered into as of October 22, 2020, between Lux Health Tech Acquisition Corp., a Delaware corporation (the “Company”), Lux Ventures VI, L.P., a Delaware limited partnership, and Lux Ventures VI Sidecar, L.P., a Delaware limited partnership (together, the “Purchasers”). RECITALS WHEREAS, the Company was f

Form of Letter Agreement among the Registrant and each director and executive officer of the Registrant.*

Exhibit 10.2 [ ● ], 2020 Lux Health Tech Acquisition Corp. 920 Broadway, 11th Floor New York, NY 10010 Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, NY 10010 Re: Initial Public Offering Ladies and Gentlemen: This letter (the “Letter Agreement”) is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) entered into by and between Lux

Certificate of Incorporation.*

Exhibit 3.1 STATE OF DELAWARE CERTIFICATE OF INCORPORATION OF LUX HEALTH TECH ACQUISITION CORP. 1.The name of this corporation is: Lux Health Tech Acquisition Corp. (the “Corporation”). 2.The address of its registered office in the State of Delaware is 251 Little Falls Drive, in the City of Wilmington, County of New Castle, State of Delaware, 19808. The name of its registered agent at such address

Form of Second Amended and Restated Certificate of Incorporation.*

Exhibit 3.3 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LUX HEALTH TECH ACQUISITION CORP. [ ● ], 2020 Lux Health Tech Acquisition Corp., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY AS FOLLOWS: 1.The name of the Corporation is “Lux Health Tech Acquisition Corp.” The original certificate of incorporation of the

Bylaws. (2)

Exhibit 3.4 BYLAWS OF LUX HEALTH TECH ACQUISITION CORP. (THE “CORPORATION”) Article I OFFICES Section 1.1.Registered Office. The registered office of the Corporation within the State of Delaware shall be located at either (a) the principal place of business of the Corporation in the State of Delaware or (b) the office of the corporation or individual acting as the Corporation’s registered agent in

Securities Subscription Agreement, dated September 4, 2020, between Lux Health Tech Acquisition Corp. and Lux Encore Sponsor, LP. (2)

Exhibit 10.5 Lux Health Tech Acquisition Corp. 920 Broadway, 11th Floor New York, NY 10010 September 4, 2020 Lux Encore Sponsor, LP 920 Broadway, 11th Floor New York, NY 10010 RE: Securities Subscription Agreement Ladies and Gentlemen: This agreement (the “Agreement”) is entered into on September 4, 2020 by and between Lux Encore Sponsor, LP, a Delaware limited partnership (the “Subscriber” or “yo

-

Lux Health Tech Acquisition Corp. 920 Broadway, 11th Floor New York, NY 10010 October 9, 2020 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn:Liz Packebusch, Staff Attorney Laura Nicholson, Special Counsel Office of Energy & Transportation Re: Lux Health Tech Acquisition Corp. Draft Registration Statement on Form S-1 Subm

Form S-1

As filed with the U.S. Securities and Exchange Commission on October 9, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Lux Health Tech Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware 6770 85-2825321 (State or other jurisdiction of incorporation or

Form of Letter Agreement between the Registrant and the Sponsor.*

Exhibit 10.1 [ ● ], 2020 Lux Health Tech Acquisition Corp. 920 Broadway, 11th Floor New York, NY 10010 Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, NY 10010 Re: Initial Public Offering Ladies and Gentlemen: This letter (the “Letter Agreement”) is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) entered into by and between Lux

First Amended and Restated Certificate of Incorporation.*

Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LUX HEALTH TECH ACQUISITION CORP. September 4, 2020 Lux Health Tech Acquisition Corp., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY AS FOLLOWS: 1. The original certificate of incorporation of the Corporation was filed with the Secretary of State of Delaware on S

Consent of Dr. Fred Moll.*

Exhibit 99.3 Consent to be Named as a Director Nominee In connection with the filing by Lux Health Tech Acquisition Corp. of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Lux

Consent of Dr. Bijan Salehizadeh.*

Exhibit 99.1 Consent to be Named as a Director Nominee In connection with the filing by Lux Health Tech Acquisition Corp. of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Lux

Form of Sponsor Warrants Purchase Agreement between Lux Health Tech Acquisition Corp. and Lux Encore Sponsor, LP.*

Exhibit 10.6 PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT THIS PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT, dated as of [•], 2020 (as it may from time to time be amended, this “Agreement”), is entered into by and between Lux Health Tech Acquisition Corp., a Delaware corporation (the “Company”), and Lux Encore Sponsor, LP, a Delaware limited partnership (the “Purchaser”). WHEREAS, the Company in

Form of Warrant Agreement between Continental Stock Transfer & Trust Company and Lux Health Tech Acquisition Corp.*

Exhibit 4.4 FORM OF WARRANT AGREEMENT between LUX HEALTH TECH ACQUISITION CORP. and CONTINENTAL STOCK TRANSFER & TRUST COMPANY Dated as of [ ● ], 2020 THIS WARRANT AGREEMENT (this “Agreement”), dated as of , 2020, is entered into by and between Lux Health Tech Acquisition Corp., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York limited purpose trust

Form of Registration Rights Agreement among Lux Health Tech Acquisition Corp. and certain security holders.*

Exhibit 10.4 FORM OF REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of , 2020, is made and entered into by and among Lux Health Tech Acquisition Company, a Delaware corporation (the “Company”), Lux Encore Sponsor, LP, a Delaware limited partnership (the “Sponsor”), and the undersigned parties listed under Holder on the signature pages hereto (each suc

Promissory Note issued in favor of Lux Encore Sponsor, LP, dated September 4, 2020. (2)

Exhibit 10.8 THIS PROMISSORY NOTE (THIS “NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COM

Form of Indemnity Agreement.*

Exhibit 10.7 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of [●], 2020, by and between Lux Health Tech Acquisition Corp., a Delaware corporation (the “Company”), and [●] (the “Indemnitee”). RECITALS WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers or in other capacities unless they are provided wit

Consent of Senator Joseph Kerrey.*

Exhibit 99.2 Consent to be Named as a Director Nominee In connection with the filing by Lux Health Tech Acquisition Corp. of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Lux

Consent to be Named as a Director Nominee

EX-99.1 7 filename7.htm Exhibit 99.1 Consent to be Named as a Director Nominee In connection with the filing by Lux Health Tech Acquisition Corp. of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the bo

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION LUX HEALTH TECH ACQUISITION CORP. September 4, 2020

Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LUX HEALTH TECH ACQUISITION CORP. September 4, 2020 Lux Health Tech Acquisition Corp., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY AS FOLLOWS: 1. The original certificate of incorporation of the Corporation was filed with the Secretary of State of Delaware on S

STATE OF DELAWARE CERTIFICATE OF INCORPORATION LUX HEALTH TECH ACQUISITION CORP.

EX-3.1 2 filename2.htm Exhibit 3.1 STATE OF DELAWARE CERTIFICATE OF INCORPORATION OF LUX HEALTH TECH ACQUISITION CORP. 1.The name of this corporation is: Lux Health Tech Acquisition Corp. (the “Corporation”). 2.The address of its registered office in the State of Delaware is 251 Little Falls Drive, in the City of Wilmington, County of New Castle, State of Delaware, 19808. The name of its registere

PROMISSORY NOTE

Exhibit 10.7 THIS PROMISSORY NOTE (THIS “NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COM

Lux Health Tech Acquisition Corp. 920 Broadway, 11th Floor New York, NY 10010

Exhibit 10.4 Lux Health Tech Acquisition Corp. 920 Broadway, 11th Floor New York, NY 10010 September 4, 2020 Lux Encore Sponsor, LP 920 Broadway, 11th Floor New York, NY 10010 RE: Securities Subscription Agreement Ladies and Gentlemen: This agreement (the “Agreement”) is entered into on September 4, 2020 by and between Lux Encore Sponsor, LP, a Delaware limited partnership (the “Subscriber” or “yo

BYLAWS LUX HEALTH TECH ACQUISITION CORP. (THE “CORPORATION”) Article I OFFICES

Exhibit 3.4 BYLAWS OF LUX HEALTH TECH ACQUISITION CORP. (THE “CORPORATION”) Article I OFFICES Section 1.1.Registered Office. The registered office of the Corporation within the State of Delaware shall be located at either (a) the principal place of business of the Corporation in the State of Delaware or (b) the office of the corporation or individual acting as the Corporation’s registered agent in

-

This is a confidential draft submission to the U.S. Securities and Exchange Commission on September 11, 2020 and is not being filed under the Securities Act of 1933, as amended. Registration No. 333- s UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Lux Health Tech Acquisition Corp. (Exact name of registrant a